Stockscreener 앱 받기
107.24
0.73%
0.78
시장 영업 전:
102.00
-5.24
-4.89%
Neurocrine Biosciences Inc 주식(NBIX)의 최신 뉴스
Neurocrine Biosciences Initiates Phase 3 Registrational Program For NBI-1117568 - marketscreener.com
Breakthrough Schizophrenia Treatment Enters Final Testing Phase with Promising 18-Point Symptom Reduction - Stock Titan
Asia-Pacific Tourette Syndrome Treatment Market Report - openPR.com
Neurocrine Biosciences publishes positive data from movement disorder study - MSN
Neurocrine Sues Zydus to Guard Ingrezza’s New Sprinkle Form - Bloomberg Law News
Canaccord cuts Neurocrine Bio stock target to $158, keeps Buy rating - Investing.com Canada
Neurocrine Biosciences (NBIX) Q1 Earnings Preview: What's in the Cards? - Yahoo Finance
Neurocrine (NBIX) Sees Price Target Adjustment Amid Market Volat - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Neurocrine Highlights INGREZZA's Long-Term Efficacy & Safety In Older Adults With Tardive Dyskinesia - Nasdaq
Neurocrine Biosciences publishes positive data from movement disorder study (NBIX:NASDAQ) - Seeking Alpha
Neurocrine (NBIX) Highlights Efficacy of Ingrezza in Older Adults with Tardive Dyskinesia | NBIX Stock News - GuruFocus
Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry - PR Newswire
Neurocrine (NBIX) Target Price Lowered by H.C. Wainwright Due to Market Pressures | NBIX Stock News - GuruFocus
Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025 - Seeking Alpha
Neurocrine Bio shares target cut to $168 by H.C. Wainwright - Investing.com India
With EPS Growth And More, Neurocrine Biosciences (NASDAQ:NBIX) Makes An Interesting Case - Yahoo Finance
Neurocrine Biosciences director sells shares worth $21.8 million - MSN
Neurocrine upgraded at RBC Capital Markets on recent selloff - MSN
Do Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Warrant Your Attention? - simplywall.st
(NBIX) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Neurocrine Biosciences: Recent Selloff Has Created A Potential Buying Opportunity (NBIX) - Seeking Alpha
Needham Upgrades Neurocrine Biosciences (LSE:0K6R) - Nasdaq
Neurocrine Biosciences Stock Price, Quotes and Forecasts | NASDAQ:NBIX - Benzinga
Neurocrine Biosciences' Positive Crenessity Physician Survey Turns This Analyst Bullish - Benzinga
What 16 Analyst Ratings Have To Say About Neurocrine Biosciences - Benzinga
Needham Upgrades Neurocrine Biosciences (NBIX) - Nasdaq
Needham Upgrades Neurocrine Biosciences to Buy From Hold, $138 Price Target - marketscreener.com
RBC Capital Upgrades Neurocrine Biosciences (LSE:0K6R) - Nasdaq
RBC Capital lifts Neurocrine Bio. stock rating to Outperform By Investing.com - Investing.com Canada
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results - Kilgore News Herald
RBC Capital Upgrades Neurocrine Biosciences (NBIX) - Nasdaq
Neurocrine Biosciences Faces Relatively Less Exposure to FDA and Tariff-Related Concerns, RBC Says - MarketScreener
Neurocrine stock upgraded at RBC Capital Markets (NBIX:NASDAQ) - Seeking Alpha
RBC upgrades Neurocrine Biosciences on low tariff exposure for key drug - TradingView
RBC Upgrades Neurocrine Biosciences to Outperform From Sector Perform, Trims Price Target to $137 From $138 - MarketScreener
Sodium Channel Blockers Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options - MSN
Tourette Syndrome Treatment Market Generated Opportunities, - openPR.com
Neurocrine Biosciences names Sanjay Keswani as chief medical officer - MSN
Neurocrine Biosciences names new Chief Medical Officer By Investing.com - Investing.com Canada
NBIXNeurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer - ADVFN
Ex-Dyne team members reconvene at Crescent - biocentury.com
Neurocrine Biosciences Appoints New Chief Medical Officer - MarketScreener
UBS cuts Neurocrine Bio. stock target to $137, keeps Buy rating - Investing.com Canada
Neurocrine Biosciences appoints new chief medical officer - The Pharma Letter
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medi - GuruFocus
Neurocrine Biosciences names new Chief Medical Officer - Investing.com India
Neurocrine Biosciences Appoints Sanjay Keswani as Chief Medical Officer - Contract Pharma
Neurocrine Biosciences Appoints Dr. Sanjay Keswani As Chief Medical Officer - marketscreener.com
Neurocrine Biosciences (NBIX) Appoints Dr. Sanjay Keswani as Chief Medical Officer - StreetInsider
UBS Lowers Price Target on Neurocrine Biosciences to $137 From $154, Keeps Buy Rating - MarketScreener
1.09%
자본화:
|
볼륨(24시간):